Premium
Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins
Author(s) -
Wieslander Jan B.,
Zhang Baimeng
Publication year - 1996
Publication title -
microsurgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.031
H-Index - 63
eISSN - 1098-2752
pISSN - 0738-1085
DOI - 10.1002/(sici)1098-2752(1996)17:2<89::aid-micr3>3.0.co;2-r
Subject(s) - medicine , heparin , hirudin , antithrombotic , partial thromboplastin time , saline , anesthesia , anticoagulant , surgery , antithrombin , thrombin , coagulation , platelet
The study was composed of two parts, arterial and venour; the 24 rabbits in each arm were divided into three equal groups and treated with either saline or 1 mg/kg body weight (bw) of a new recombinant hirudin HBW 023 given as a single dose or standard heparin 1 mg/kg bw followed by quarter doses of heparin every half hour. Both arms included a control group given equal volumes of saline. The study continued for 2 hours. The following parameters were evaluated: bleeding times from the arteriotomy/venotomy, patency rates, and the wieghts of thrombotic materials. Plasma samples were taken for evaluation of anti‐factor IIa (anti‐FIIa), anti‐factor Xa (anti‐Fxa), and activated partial thromboplastin time (APTT). The bleeding times were significantly prolonged but were still within clinically acceptable levels, following both HBW 023 and heparin treatment. A corresponding reduction in thrombotic materials was simultaneously registered in the arterial and venous arms follwing HBW 023 and heparin treatment. Hirudin (HBW 023) significantly improved the reduction compared with the heparin group in the venous study. Heparin treatment caused expected high levels of anti‐Fxa and prolonged APTT, but hirudin, being at least as effective in antithrombotic potency, changed the pre‐treatment levels only slightly. Anti FIIa levels were immediately increased by both heparin and hirudin (the highest levels) but reached low levels after 2 hours of single‐dose hirudin treatment, despite a simultaneously excellent antithrombotic effect. We conclude that the new recombinant hirudin HBW 023, like standard heparin, is a highly efficient antithrombotic agent in both small arteries and veins following severe vessel wall trauma. The bleeding times were simultaneously prolonged significantly (still within accepatble limits) following both heparin and HBW 023 treatment in the arterial arm but were only prolonged following heparin treatment in the venous arm. The advantage of r‐hirudin HBW 023 was furthermore the single dose administration. © 1996 Wiley‐Liss, Inc.